8637 RESULTS
COMMENT The compound GV-971, Sodium oligomannate, was recently tested in a people who, based on clinical criteria, had mild to moderate dementia believed to be due to Alzheimer’s disease. Over a 36-week period, participants on GV-971 performed better than placebo ...
COMMENT Approval in China for a new treatment for Alzheimer’s disease is encouraging. We await publication of the study that led to approval. From the data presented at CTAD, cholinesterase inhibitors were not allowed and the drug worked best for those with a ...
COMMENT Due to the known nature of their mutations, autosomal-dominant cohorts are powerful models to understand Alzheimer's pathobiology. Any time an ADAD carrier significantly deviates from their expected trajectory, there is the possibility to gain ...
COMMENT One should always be aware that this is a single case report. It remains possible there are other reasons for this woman’s protection. However, there are precedents for other APOE variants that change risk of AD (Kamboh et al., 1999; Medway et al., 2014). ...
COMMENT Reiman et al. is a very interesting study, showing that the risk of Alzheimer's disease for APOE-ε2 homozygotes is extremely low even when compared with APOE-ε2 heterozygotes. This result, even not surprising, has an impact on how we should think ...
COMMENT In general the data confirm previous findings, and highlights that intervening in APOE-related mechanisms is still a useful therapeutic avenue for AD. The neuropathological confirmation in a subset of 5,000 participants is a strong asset. It is of ...
COMMENT While much of the genetic study of AD focuses on risk factors and causes of the disease, it is at least as important to identify corresponding protective factors. This study takes this approach by focusing on factors that protect/delay onset of disease by ...
COMMENT The finding that this individual with a PS1 E280A mutation did not develop symptoms of cognitive impairment due to AD until her early 70s is very intriguing. The fact that she also has the ApoE3 Christchurch mutation, has very high amyloid deposition, but ...
COMMENT This paper is exciting and remarkable for various reasons. PET imaging showed very high amyloid load, but little tau pathology and glucose metabolism in the healthy range, supporting a greater role of tau than amyloid in cognitive injury in AD. The ...
COMMENT This elegant study provides proof-of-principle evidence that the cascading component of the “amyloid cascade hypothesis” can be unhinged. The study shows that a lot of amyloid plaque accumulation does not necessarily lead to tau pathology and ...
COMMENT This is an exciting paper, which provides a possible mechanistic link between slow-wave neuronal activity during NREM sleep and pulsations in CSF flow. It offers a new insight into how sleep-related changes in neuronal activity potentially alter CSF ...
COMMENT We and Weigand et al. both take advantage of the availability of tau PET to ask important—but quite different—questions about AD pathophysiology. APOE ɛ4 is well-known to be associated with amyloidosis, but whether this allele may directly impact tau has ...
COMMENT Two interesting papers being published look at the effects of APOE genotype on different aspects of AD, in particular tau pathology and cognitive progression of disease. Bondi and colleagues studied 297 older adults without dementia being followed in ADNI ...
COMMENT This structure is in fact quite different from the Aβ40 fibrils grown in vitro (from incubation of synthetic or expressed Aβ40 in aqueous), and also different from a previously published structure of ex vivo fibrils by Tycko et al. The quaternary ...
COMMENT This work by Jucker and Fändrich is a very important step forward in the structural biology of Aβ, since the amyloid has been purified from human AD material. This is the first structure of its kind (a solid state NMR structure of Aβ(1-40) has been ...
